EIKN

MILLBRAE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that the first patient has been dosed in TeLuRide-008, a Phase 2/3 registrational study evaluating EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy as first-line therapy for treatment-naïve patients with stage 4 Non-Small Cell Lung Cancer (NSCLC).

Presentations to cover updates across Eikon's clinical pipeline including:  Updated data from TeLuRide-005, an ongoing Phase 2 trial of EIK1001, a TLR7/8 dual agonist, plus pembrolizumab and chemotherapy in stage 4 non-small cell lung cancer (NSCLC) Updated cohort data from an ongoing Phase 1/2 study of EIK1003, a highly selective non-brain penetrant PARP1 inhibitor, as monotherapy and in combination with chemotherapy in advanced solid tumors Initial data from a Phase 1/2 study of EIK1003 in combination with the novel hormonal agent abiraterone in metastatic prostate cancer Initial results from an ongoing Phase 1/2 study of EIK1004, a highly selective CNS-penetrant PARP1 inhibitor in advanced solid malignancies Initial safety, tolerability and pharmacokinetics data for EIK1005, a Werner (WRN) helicase inhibitor MILLBRAE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the acceptance of seven abstracts covering progress across its lead programs at the 2026 European Society of Medical Oncology (ESMO) Congress in Madrid, Spain.

Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community

Eikon Therapeutics is initiated with a cautious buy, leveraging industry-leading management and a robust oncology-focused pipeline. EIKN's ASCO data for EIK1001 in NSCLC showed a 63.1% ORR and favorable safety, but the market response was muted. Cash reserves of $596m provide a runway into 2027 despite high R&D burn; valuation is now below cash, reflecting skepticism.

MILLBRAE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today reported first quarter 2026 financial results and provided updates on its lead clinical programs.